The study is a randomized, double-blind, placebo-controlled, multiple-dose, pilot study of
orally-administered ivacaftor in subjects with chronic obstructive pulmonary disease.
Subjects will be administered the study drug ivacaftor 150 mg (or placebo) twice daily (BID).